Wednesday October 17, 11:01 am Eastern Time
Press Release
SOURCE: Variagenics, Inc.
Variagenics To Report Third Quarter Financial
Results On November 1, 2001
Company to Host Conference Call at 11:00 a.m.
CAMBRIDGE, Mass., Oct. 17 /PRNewswire/ -- Variagenics, Inc. (Nasdaq: VGNX - news), a leader in pharmacogenomics,
today announced that the Company will report its Third Quarter financial results on Thursday, November 1, 2001 at 7:30 a.m.
and hold a conference call at 11:00 a.m. Eastern Time. Taylor J. Crouch, President and CEO, will lead the call.
Date: Thursday, November 1, 2001
Time: 11:00 a.m. Eastern Time
Conference call numbers
Toll-free: (800) 289-0494
Toll/international: (913) 981-5520
Webcast: www.variagenics.com
There will be a replay (beginning at 3:00 p.m.) of the conference call for five days. To replay the call, please dial (888)
203-1112 in the U.S. and (719) 457-0820, internationally. The access code is: 733831.
Variagenics, inc. applies its pharmacogenomic technologies to the discovery, development and commercialization of
individualized drugs and companion molecular diagnostic products. The Company identifies clinically important genetic
variations, including SNPs and haplotypes (groups of SNPs), and uses this information to improve and enhance drugs in
development and to identify and validate new drug targets. Variagenics is leveraging its technologies and expertise -- including
its new NuCleave(TM) genotyping and haplotyping analysis platform -- into solutions for pharmaceutical companies and clinical
laboratories seeking to optimize therapeutic outcomes for patients. For more information visit the Company's website at
variagenics.com
This press release may contain forward-looking statements. Such statements are based on management's current expectations
and are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ
materially from those referred to or implied in such statements. These risks are identified in the Company's filings with the
Securities and Exchange Commission, including but not limited to, the Company's Annual Report on Form 10-K for the year
ended December 31, 2000. The Company does not intend to update any of the forward-looking statements after the date of
this release to conform these statements to actual results or to changes in our expectations, except as required by law.
SOURCE: Variagenics, Inc. |
